Natera, Inc. announced the results of a Stanford University School of Medicine-led study evaluating its personalized molecular residual disease (MRD) test, Signatera, in patients with soft tissue and bone sarcomas. The findings were presented at the 2025 Society of Surgical Oncology (SSO) Annual Meeting in March.
This study represents the largest sarcoma cohort to date using personalized circulating-tumor DNA (ctDNA) monitoring, with approximately 200 patients and over 2,100 plasma samples across multiple distinct subtypes. Sarcomas are a heterogeneous group of rare cancers, making monitoring treatment response and recurrence particularly difficult.
Key findings included an overall sensitivity of 89% and specificity of 100% for Signatera across the diverse sarcoma subtypes. Specifically, leiomyosarcoma, the most common subtype in the cohort, demonstrated a sensitivity of 93% and specificity of 100%. These results support Signatera’s ability to track disease status with precision in a difficult-to-monitor cancer.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.